Skip to main content
Original communication

The TOPOS study

Safety and efficacy of an oblique common iliac vein stent in patients with post-thrombotic syndrome – two-year results of the TOPOS study

Published Online:https://doi.org/10.1024/0301-1526/a001118

Summary:Background: We aimed to study the long-term safety and efficacy of oblique venous stents for post-thrombotic syndrome (PTS) with iliac vein compression. Patients and methods: In the multinational, prospective, single-arm TOPOS study, PTS patients scheduled for endovascular therapy with the sinus-Obliquus® stent and optional distal extension with the sinus-Venous® or sinus-XL Flex® stent were enrolled at eight European vascular centres between October 2016 and December 2020. The primary outcome was primary stent patency at 24 months, and secondary outcomes included the clinical course of PTS (Villalta score, revised Venous Clinical Severity Score [rVCSS], Visual Analog Scale [VAS] of pain), quality of life changes (Chronic Venous Insufficiency Quality of Life Questionnaire, CIVIQ-20), and device-related complications. Results: We enrolled 60 patients (mean age 46±15 years, 68% women, 13% active ulcers): 80% required stent extension (70% below the inguinal ligament). The primary patency rate at 24 months was 80.7% (95%CI 68.1–90.0%); it was higher in patients without vs. those with stent extension (90.9% vs. 78.3%, p=.01). Compared to baseline, the Villalta, rVCSS, pain VAS, and CIVIQ-20 decreased by a median of 8 (interquartile range (IQR): 4–11), 5 (IQR: 3–7), 3 (IQR: 2–5), and 17 (IQR: 6–22) points, respectively; p<.001 for all parameters. Overall, 9 events of acute stent occlusion, 4 symptomatic stent stenosis, and 1 pulmonary embolism occurred. We did not observe major bleeding events or contralateral thrombosis. Conclusions: Endovascular treatment with the oblique stent and optional stent extension was safe and resulted in high patency rates at 24 months. The reduction in PTS severity was substantial and persisted over 2-year follow-up.

References

  • 1 Duarte-Gamas L, Rocha-Neves JP, Pereira-Neves A, Dias-Neto M, Baekgaard N. Contralateral deep vein thrombosis after stenting across the iliocaval confluence in chronic venous disease – A systematic review. Phlebology. 2020;35(4):221–30. https://doi.org/10.1177/0268355519889873 First citation in articleCrossref MedlineGoogle Scholar

  • 2 Dabir D, Feisst A, Thomas D, Luetkens JA, Meyer C, Kardulovic A, et al. Physical properties of venous stents: an experimental comparison. Cardiovasc Intervent Radiol. 2018;41(6):942–50. https://doi.org/10.1007/s00270-018-1916-1 First citation in articleCrossref MedlineGoogle Scholar

  • 3 Sebastian T, Lichtenberg M, Schlager O, Jalaie H, de Graaf R, Erbel C, et al. Early clinical outcomes for treatment of post-thrombotic syndrome and common iliac vein compression with a hybrid Oblique self-expanding nitinol stent – the TOPOS study. Vasa. 2020;49(4):301–8. https://doi.org/10.1024/0301-1526/a000857 First citation in articleLinkGoogle Scholar

  • 4 Sebastian T, Barco S, Lichtenberg M, Stahlhoff S, Schlager O, Jalaie H, et al. Twelve-month clinical outcomes of a hybrid oblique self-expanding nitinol stent used for the treatment of post-thrombotic syndrome with common iliac vein compression: The TOPOS study. Vasc Med. 2021;26(5):569–71. https://doi.org/10.1177/1358863X211017658 First citation in articleCrossref MedlineGoogle Scholar

  • 5 Tang TY, Yap CJQ, Chan SL, Soon SXY, Lim MHH, Tan JWH. Midterm outcomes (2 years) using the VenovoTM and Sinus ObliquusTM venous stents in the treatment of non-thrombotic and post-thrombotic iliac vein lesions – Results from a multi-centre Asian cohort. Phlebology. 2022;37(7):543–7. https://doi.org/10.1177/02683555221094401 First citation in articleCrossref MedlineGoogle Scholar

  • 6 Tang TY, Lim MH, Damodharan K, Yap CJ, Lee SQ, Yap HY, et al. Use of the VENOVOTM and Sinus ObliquusTM venous stents in the treatment of non-thrombotic or post-thrombotic iliac vein lesions – Short-term results from a multi-centre Asian cohort. Phlebology. 2021;36(1):70–8. https://doi.org/10.1177/0268355520946219 First citation in articleCrossref MedlineGoogle Scholar

  • 7 Lichtenberg M, de Graaf R, Stahlhoff WF, Özkapi A, Simon M, Breuckmann F. Patency rates, safety and clinical results of the sinus-Obliquus venous stent in the treatment of chronic ilio-femoral venous outflow obstruction – data from the Arnsberg venous registry. Vasa. 2019;48(3):270–5. https://doi.org/10.1024/0301-1526/a000772 First citation in articleLinkGoogle Scholar

  • 8 Stuck AK, Kunz S, Baumgartner I, Kucher N. Patency and clinical outcomes of a dedicated, self-expanding, hybrid oblique stent used in the treatment of common iliac vein compression. J Endovasc Ther. 2017;24(1):159–66. https://doi.org/10.1177/1526602816676803 First citation in articleCrossref MedlineGoogle Scholar

  • 9 Dake MD, O’Sullivan G, Shammas NW, Lichtenberg M, Mwipatayi BP, Settlage RA, VERNACULAR Trial Investigators. Three-year results from the venovo venous stent study for the treatment of iliac and femoral vein obstruction. Cardiovasc Intervent Radiol. 2021;44(12):1918–29. https://doi.org/10.1007/s00270-021-02975-2 First citation in articleCrossref MedlineGoogle Scholar

  • 10 Hofmann LR, Gagne P, Brown JA, Saunders A, Comerota A, Investigators VS. Twelve-month end point results from the evaluation of the Zilver Vena venous stent in the treatment of symptomatic iliofemoral venous outflow obstruction (VIVO clinical study). J Vasc Surg Venous Lymphat Disord. 2023; https://doi.org/10.1016/j.jvsv.2022.12.066 First citation in articleCrossref MedlineGoogle Scholar

  • 11 Murphy E, Gibson K, Sapoval M, Dexter DJ, Kolluri R, Razavi M, et al. Pivotal study evaluating the safety and effectiveness of the Abre venous self-expanding stent system in patients with symptomatic iliofemoral venous outflow obstruction. Circ Cardiovasc Interv. 2022;15(2):e010960. https://doi.org/10.1161/circinterventions.121.010960 First citation in articleCrossref MedlineGoogle Scholar

  • 12 Razavi MK, Gagne P, Black S, Sadek M, Nicolini P, Weinberg I, et al. Midterm and long-term outcomes following dedicated endovenous nitinol stent placement for symptomatic iliofemoral venous obstruction: three- to 5-year results of the VIRTUS study. J Vasc Interv Radiol. 2022;33(12):1485–91.e1. https://doi.org/10.1016/j.jvir.2022.08.028 First citation in articleCrossref MedlineGoogle Scholar

  • 13 Razavi MK, Jaff MR, Miller LE. Safety and effectiveness of stent placement for iliofemoral venous outflow obstruction: systematic review and meta-analysis. Circ Cardiovasc Interv. 2015;8(10):e002772. https://doi.org/10.1161/circinterventions.115.002772 First citation in articleCrossref MedlineGoogle Scholar

  • 14 Sebastian T, Gnanapiragasam S, Spirk D, Engelberger RP, Moeri L, Lodigiani C, et al. Self-expandable nitinol stents for the treatment of nonmalignant deep venous obstruction. Circ Cardiovasc Interv. 2020;13(12):e009673. https://doi.org/10.1161/circinterventions.120.009673 First citation in articleCrossref MedlineGoogle Scholar

  • 15 Sebastian T, Spirk D, Engelberger RP, Dopheide JF, Baumann FA, Barco S, et al. Incidence of stent thrombosis after endovascular treatment of iliofemoral or caval veins in patients with the postthrombotic syndrome. Thromb Haemost. 2019;119(12):2064–73. https://doi.org/10.1055/s-0039-1697955 First citation in articleCrossref MedlineGoogle Scholar

  • 16 Moini M, Zafarghandi MR, Taghavi M, Salimi J, Tadayon B, Mohammad Sadat SA, et al. Venoplasty and stenting in post-thrombotic syndrome and non-thrombotic iliac vein lesion. Minim Invasive Ther Allied Technol. 2020;29(1):35–41. https://doi.org/10.1080/13645706.2019.1580748 First citation in articleCrossref MedlineGoogle Scholar

  • 17 Razavi M, Marston W, Black S, Bentley D, Neglen P. The initial report on 1-year outcomes of the feasibility study of the VENITI VICI VENOUS STENT in symptomatic iliofemoral venous obstruction. J Vasc Surg Venous Lymphat Disord. 2018;6(2):192–200. https://doi.org/10.1016/j.jvsv.2017.10.014 First citation in articleCrossref MedlineGoogle Scholar